Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational products.

The company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, also known as Pixclara. This is a positron emission tomography (PET) imaging agent designed for the characterization of recurrent or progressive glioma, a form of brain cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for its review.

This regulatory milestone is viewed positively by the market as it addresses a critical unmet medical need. TLX101-Px has previously been granted both Orphan Drug and Fast Track designations by the FDA, which are intended to facilitate the development and review of drugs for serious conditions. The company's FY 2026 financial guidance explicitly states it does not include any revenue contribution from TLX101-Px, indicating that the stock movement is driven by the future potential and reduced regulatory risk associated with this application acceptance.